🚀 VC round data is live in beta, check it out!
Relay Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Relay Therapeutics and similar public comparables like Galecto, Intellia Therapeutics, Vericel, Enliven Therapeutics and more.
Relay Therapeutics Overview
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Founded
2015
HQ
Employees
323
Website
Sectors
Financials (LTM)
EV
$1B
Relay Therapeutics Financials
Relay Therapeutics reported last 12-month revenue of $13M and negative EBITDA of ($294M).
In the same LTM period, Relay Therapeutics generated $13M in gross profit, ($294M) in EBITDA losses, and had net loss of ($274M).
Revenue (LTM)
Relay Therapeutics P&L
In the most recent fiscal year, Relay Therapeutics reported revenue of $15M and EBITDA of ($299M).
Relay Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $13M | XXX | $15M | XXX | XXX | XXX |
| Gross Profit | $13M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($294M) | XXX | ($299M) | XXX | XXX | XXX |
| EBITDA Margin | (2185%) | XXX | (1948%) | XXX | XXX | XXX |
| EBIT Margin | (2228%) | XXX | (1972%) | XXX | XXX | XXX |
| Net Profit | ($274M) | XXX | ($276M) | XXX | XXX | XXX |
| Net Margin | (2039%) | XXX | (1801%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Relay Therapeutics Stock Performance
Relay Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Relay Therapeutics' stock price is $10.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-1.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRelay Therapeutics Valuation Multiples
Relay Therapeutics trades at 90.4x EV/Revenue multiple, and (4.1x) EV/EBITDA.
EV / Revenue (LTM)
Relay Therapeutics Financial Valuation Multiples
As of March 21, 2026, Relay Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Relay Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Relay Therapeutics has a P/E ratio of (6.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 90.4x | XXX | 79.1x | XXX | XXX | XXX |
| EV/EBITDA | (4.1x) | XXX | (4.1x) | XXX | XXX | XXX |
| EV/EBIT | (4.1x) | XXX | (4.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 96.2x | XXX | — | XXX | XXX | XXX |
| P/E | (6.5x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | (5.5x) | XXX | (5.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Relay Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Relay Therapeutics Margins & Growth Rates
Relay Therapeutics' revenue in the last 12 month declined by (27%).
Relay Therapeutics' revenue per employee in the last FY averaged $0.0M.
Relay Therapeutics' rule of 40 is (2212%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Relay Therapeutics' rule of X is (2252%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Relay Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (27%) | XXX | (58%) | XXX | XXX | XXX |
| EBITDA Margin | (2185%) | XXX | (1948%) | XXX | XXX | XXX |
| EBITDA Growth | (9%) | XXX | (9%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2212%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (2252%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 407% | XXX | 369% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1900% | XXX | 1702% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2072% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Relay Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Galecto | XXX | XXX | XXX | XXX | XXX | XXX |
| Intellia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vericel | XXX | XXX | XXX | XXX | XXX | XXX |
| Enliven Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Faes Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Relay Therapeutics M&A Activity
Relay Therapeutics acquired XXX companies to date.
Last acquisition by Relay Therapeutics was on XXXXXXXX, XXXXX. Relay Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Relay Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRelay Therapeutics Investment Activity
Relay Therapeutics invested in XXX companies to date.
Relay Therapeutics made its latest investment on XXXXXXXX, XXXXX. Relay Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Relay Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Relay Therapeutics
| When was Relay Therapeutics founded? | Relay Therapeutics was founded in 2015. |
| Where is Relay Therapeutics headquartered? | Relay Therapeutics is headquartered in United States. |
| How many employees does Relay Therapeutics have? | As of today, Relay Therapeutics has over 323 employees. |
| Who is the CEO of Relay Therapeutics? | Relay Therapeutics' CEO is Sanjiv K. Patel. |
| Is Relay Therapeutics publicly listed? | Yes, Relay Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Relay Therapeutics? | Relay Therapeutics trades under RLAY ticker. |
| When did Relay Therapeutics go public? | Relay Therapeutics went public in 2020. |
| Who are competitors of Relay Therapeutics? | Relay Therapeutics main competitors are Galecto, Intellia Therapeutics, Vericel, Enliven Therapeutics. |
| What is the current market cap of Relay Therapeutics? | Relay Therapeutics' current market cap is $2B. |
| What is the current revenue of Relay Therapeutics? | Relay Therapeutics' last 12 months revenue is $13M. |
| What is the current revenue growth of Relay Therapeutics? | Relay Therapeutics revenue growth (NTM/LTM) is (27%). |
| What is the current EV/Revenue multiple of Relay Therapeutics? | Current revenue multiple of Relay Therapeutics is 90.4x. |
| Is Relay Therapeutics profitable? | No, Relay Therapeutics is not profitable. |
| What is the current EBITDA of Relay Therapeutics? | Relay Therapeutics has negative EBITDA and is not profitable. |
| What is Relay Therapeutics' EBITDA margin? | Relay Therapeutics' last 12 months EBITDA margin is (2185%). |
| What is the current EV/EBITDA multiple of Relay Therapeutics? | Current EBITDA multiple of Relay Therapeutics is (4.1x). |
| What is the current FCF of Relay Therapeutics? | Relay Therapeutics' last 12 months FCF is ($222M). |
| What is Relay Therapeutics' FCF margin? | Relay Therapeutics' last 12 months FCF margin is (1650%). |
| What is the current EV/FCF multiple of Relay Therapeutics? | Current FCF multiple of Relay Therapeutics is (5.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.